Search results
The Lung dataset is a comprehensive dataset that contains nearly all the PLCO study data available for lung cancer screening, incidence, and mortality analyses. The dataset contains one record for each of the approximately 155,000 participants in the PLCO trial.
- Ancillary Studies
Aug 16, 2024 Accepting Requests for Specimen Verification...
- Other Cancer Sites
Datasets for cancer sites other than prostate, lung,...
- Hematopoietic
The following PLCO Hematopoietic dataset(s) are available...
- Chronic Conditions
The following PLCO Chronic Conditions dataset(s) are...
- Questionnaires
The following PLCO Questionnaires dataset(s) are available...
- SCU
The following PLCO SCU dataset(s) are available for delivery...
- Male Breast
The following PLCO Male Breast dataset(s) are available for...
- Biliary
The following PLCO Biliary dataset(s) are available for...
- Ancillary Studies
4 wrz 2024 · A new benchmark for targeted therapies in lung cancer treatment. AEs, adverse events; HR, hazard ratio; NR, not reached; PFS, progression-free survival. Open in viewer.
7 wrz 2022 · Clinical trials investigate every aspect of lung cancer care, including: Prevention trials explore new ways to prevent lung cancer from developing in people who have never had the disease or recurring (returning) in those who have. Screening trials develop and test new ways to detect lung cancer.
Current research is looking at ways to improve the diagnosis and treatment of lung cancer. Find out about clinical trials and how to take part.
8 maj 2024 · Learn what's new in lung cancer research through recent findings from studies that used immunotherapy and targeted therapies to treat lung cancer. Find how research efforts to detect lung cancer early are using blood and sputum samples and even artificial intelligence.
15 lut 2021 · Information related to 6092 registered lung cancer trials was downloaded. Phase II trials were in the majority, comprising nearly 48.7% of total clinical trials with industry the major sponsor (41.3%) followed by NIH (12.3%). Multicenter studies were the norm accounting for 47.9% and the main study location was the USA (50.9%).
CDAS provides extensive public documentation for each study, including a trial summary, an overview of the data collected, and a searchable database of research projects and publications. If you are interested in obtaining study data, you may begin a CDAS project for that study.